Close Menu

NEW YORK (GenomeWeb) – With a CHF 1 million ($1.1 million) addition to its Series B financing round announced this week, Swiss proteomics firms ProteoMedix plans to begin clinical validation of its four-protein prostate cancer test.

The company will this year start clinical studies for the test in central Europe, the UK, and the US, enrolling a total of 1,500 patients, Co-founder and CEO Ralph Schiess told GenomeWeb. He added that ProteoMedix hopes to begin commercial roll-out of the test in the next two to three years, launching first in Europe and then in the US.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.